Pharmacovigilance is evolving as drug complexity and adverse event reporting grow. Traditional two-vendor models—separating safety services and technology—create inefficiencies, misaligned processes, and higher costs. IQVIA’s integrated model unites both under one roof, enabling seamless collaboration, faster compliance, and lower expenses. This combined approach fosters continuous feedback between PV experts and tech teams, ensuring platforms are intuitive and regulations are met globally. Automation further boosts efficiency, handling tasks like adverse event intake, coding, translations, and report scheduling. In 2022, IQVIA processed 2.8M+ cases across 160+ countries with 99% quality compliance.

Join for free to read